Galectin Therapeutics Inc. Announces Publication of Galectin Symposium Proceedings by the American Chemical Society

  Galectin Therapeutics Inc. Announces Publication of Galectin Symposium
  Proceedings by the American Chemical Society

Business Wire

NORCROSS, Ga. -- January 28, 2013

Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today announced
that the American Chemical Society (ACS), as part of its ACS Symposium Series,
has published online the proceedings from the galectin-focused symposium
hosted by Galectin Therapeutics, Galectins and Disease Implications for
Targeted Therapeutics. The book is edited by Dr. Anatole Klyosov, Chief
Scientist at Galectin, and Dr. Peter G. Traber, Chief Executive Officer and
Chief Medical Officer of Galectin.

“The reviews in this compendium by international experts provide a clear
picture of the emerging importance of galectin proteins in a wide variety of
diseases,” said Dr. Traber. “As evidenced by this symposium, there is great
interest in continuing to expand the therapeutic applications for
galectin-targeted proteins and we are thrilled that Galectin Therapeutics is
at the forefront of that translational medicine, with compounds in development
for the treatment of liver fibrosis, including non-alcoholic steatohepatitis
(NASH) liver disease, and advanced metastatic melanoma.”

This peer reviewed compendium focuses on galectins in disease and was inspired
by topics discussed at the international symposium hosted by Galectin
Therapeutics, “Galectin Function and Therapeutics”, which took place in Boston
in September, 2012. This comprehensive guide, organized as a series of
mini-reviews by leading experts on galectins and their biomedical and
therapeutic applications, provides current understandings of galectin proteins
and their role in inflammatory pathophysiology, as well as their potential
utility in drug design of targeted therapeutics. It is designed to help
chemical scientists, biologists, oncologists and gastroenterologists to
understand the important role that galectins play in disease and that
carbohydrate-based drugs may have in treatment of liver fibrosis, cancer and
other inflammatory diseases.

These symposium proceedings are currently available at Print copies of the book are expected
to be available from Oxford University Press in Spring, 2013 under ISBN:

About Galectin Therapeutics Inc.

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at

About ACS (The American Chemical Society)

ACS is a congressionally chartered independent membership organization which
represents professionals at all degree levels and in all fields of chemistry
and sciences that involve chemistry. The ACS Symposium Series contains
high-quality books which are peer-reviewed, at the book and chapter level, and
are developed from the ACS technical divisions’ symposia. Each chapter is
carefully authored by an expert in the field.

Forward Looking Statement disclaimer

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.


Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO & CMO
Press spacebar to pause and continue. Press esc to stop.